12:13 PM EST - Warnex Inc. : and Epigenomics AG announced today the launch of Warnex's Septin9 blood testing service for colorectal cancer in Canada. Warnex's Septin9 test is based on Epigenomics' patented biomarker Septin9 and DNA methylation technologies. Warnex is the first laboratory to offer Septin9 testing in Canada, after obtaining the non-exclusive rights from Epigenomics in May 2010. Prior to its launch, Warnex's Septin9 test was independently developed and successfully validated using clinical blood samples from colorectal cancer patients and individuals with no apparent disease as verified by colonoscopy. Warnex Inc.
shares T.WNX are trading up $0.01 at $0.11.
